DAWN insider buying and SEC filings, explained
Day One Biopharmaceuticals, Inc. · CIK 1845337
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$672K
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Feb 17, 2026 | Sale | Jeremy Bender (CEO and Director) sold 15,459 shares at about $11.60 ($179K). Holdings down 7% to 204,603 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 18, 2026 |
| Feb 17, 2026 | Sale | Lauren Merendino (Chief Commercial Officer) sold 5,814 shares at about $11.60 ($67K). Holdings down 9% to 60,157 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 18, 2026 |
| Feb 17, 2026 | Sale | Adam Dubow (Gen Counsel & Secretary) sold 6,395 shares at about $11.60 ($74K). Holdings down 8% to 72,694 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 18, 2026 |
| Feb 17, 2026 | Sale | Michael Vasconcelles (Head of Research and Dev.) sold 2,728 shares at about $11.60 ($32K). Holdings down 38% to 4,397 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 18, 2026 |
| Feb 17, 2026 | Sale | Charles N York II (CFO) sold 6,065 shares at about $11.60 ($70K). Holdings down 2% to 312,025 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 18, 2026 |
| Nov 17, 2025 | Sale | Jeremy Bender (CEO and Director) sold 15,894 shares at about $8.91 ($142K). Holdings down 8% to 177,165 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 18, 2025 |
| Nov 17, 2025 | Sale | Lauren Merendino (Chief Commercial Officer) sold 3,726 shares at about $8.91 ($33K). Holdings down 7% to 50,809 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 18, 2025 |
| Nov 17, 2025 | Sale | Adam Dubow (Gen Counsel & Secretary) sold 4,319 shares at about $8.91 ($38K). Holdings down 6% to 62,626 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 18, 2025 |
| Nov 17, 2025 | Sale | Charles N York II (CFO) sold 4,062 shares at about $8.91 ($36K). Holdings down 1% to 294,715 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 18, 2025 |
39 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow DAWN in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.